Preview

谢切诺夫学报

高级搜索

Familial co-occurrence of diffuse leiomyomatosis and Alport syndrome: a clinical case report

https://doi.org/10.47093/2218-7332.2025.16.4.1344

摘要

Alport syndrome (AS) is a hereditary nephropathy caused by mutations in the COL4A3, COL4A4, and COL4A5 genes. Rare contiguous COL4A5–COL4A6 alterations cause AS with diffuse leiomyomatosis (AS-DL).

Case report. A 16-year-old male had mild proteinuria, hematuria, hearing loss and myopia since childhood. Estimated glomerular filtration rate was 82.8 mL/min/1.73 m2. Kidney biopsy showed segmental mesangial sclerosis; immunofluorescence was negative. Electron microscopy demonstrated diffuse glomerular basement membrane thinning and podocyte foot-process effacement. Two deceased brothers had end stage kidney disease; the mother had hematuria, uterine myoma, and a benign bladder tumor. A diagnosis of X-linked AS was established according to the Flinter criteria and nephroprotective treatment was initiated. Since 2024, the patient had complained of epigastric symptoms. An endoscopy revealed a 2-cm gastric submucosal lesion. A whole-exome sequencing identified a hemizygous missense variant in COL4A5 and a COL4A6 exon 1–2 deletion, confirming AS-DL.

Discussion. This case demonstrates the co-occurrence of AS-DL and shows that early pedigree assessment, combined with integrated clinicopathologic-genetic evaluation in a multidisciplinary framework, enables a timely diagnosis of atypical familial AS-DL and improves clinical management.

关于作者

М. Boltaboeva
Аndijan State Мedical Institute
乌兹别克斯坦


A. Haydarov
Аndijan State Мedical Institute
乌兹别克斯坦


M. Ganieva
Аndijan State Мedical Institute
乌兹别克斯坦


D. Kholmatov
Аndijan State Мedical Institute
乌兹别克斯坦


O. Efimenko
Аndijan State Мedical Institute
乌兹别克斯坦


L. Rakhmanova
Tаshkent State Medical University
乌兹别克斯坦


参考

1. Gregorio V., Caparali E.B., Shojaei A., et al. Alport syndrome: Clinical spectrum and therapeutic advances. Kidney Med. 2023 Mar; 5(5): 100631. https://doi.org/10.1016/j.xkme.2023.100631. PMID: 37122389

2. Huang H.X., Tsai I.J., Greenbaum L.A. Alport syndrome: Expanding diagnosis and treatment. Pediatr Neonatol. 2025 Feb; 66(Suppl1): S13–S17. https://doi.org/10.1016/j.pedneo.2024.10.005. Epub 2024 Oct 30. PMID: 39521677

3. Puapatanakul P., Miner J.H. Alport syndrome and Alport kidney diseases – elucidating the disease spectrum. Curr Opin Nephrol Hypertens. 2024 May; 33(3): 283–290. https://doi.org/10.1097/MNH.0000000000000983. Epub 2024 Mar 13. PMID: 38477333

4. Savige J. Heterozygous pathogenic COL4A3 and COL4A4 variants (autosomal dominant Alport syndrome) are common, and not typically associated with end-stage kidney failure, hearing loss, or ocular abnormalities. Kidney Int Rep. 2022 Jun; 7(9): 1933–1938. https://doi.org/10.1016/j.ekir.2022.06.001. PMID: 36090501

5. Gibson J., Fieldhouse R., Chan M.M.Y., et al. Prevalence estimates of predicted pathogenic COL4A3-COL4A5 variants in a population sequencing database and their implications for Alport syndrome. J Am Soc Nephrol. 2021 Sep; 32(9): 2273–2290. https://doi.org/10.1681/ASN.2020071065. Epub 2021 Jun 18. PMID: 34400539

6. Torra R., Lipska-Zietkiewicz B., Acke F., et al. Diagnosis, management and treatment of the Alport syndrome – 2024 guideline on behalf of ERKNet, ERA and ESPN. Nephrol Dial Transplant. 2025 May; 40(6): 1091-1106. https://doi.org/10.1093/ndt/gfae265. PMID: 39673454

7. Zhou X., Wang J., Mao J., Ye Q. Clinical manifestations of Alport syndrome-diffuse leiomyomatosis patients with contiguous gene deletions in COL4A6 and COL4A5. Front Med (Lausanne). 2021 Oct; 8: 766224. https://doi.org/10.3389/fmed.2021.766224. PMID: 34778325

8. Takeda F.R., De Meira J.D. Junior, Sallum R.A.A. A case report of esophageal leiomyoma in Alport’s syndrome treated with roboticassisted distal myotomy: A surgical technique to avoid esophagectomy. International Journal of Surgery Case Reports. 2023 Jun; 108: 108433. https://doi.org/10.1016/j.ijscr.2023.108433. PMID: 37352772

9. Kashtan C.E. Alport syndrome: Achieving early diagnosis and treatment. Am J Kidney Dis. 2021 Feb; 77(2): 272–279. https://doi.org/10.1053/j.ajkd.2020.03.026. Epub 2020 Jul 22. PMID: 32712016

10. Алексеева Т.А., Аксенова М.Е., Заикова Н.М. Особенности течения и диагностики Х-сцепленного синдрома Альпорта с диффузным лейомиоматозом желудочно-кишечного тракта: клинический случай. Нефрология и диализ. 2025; 27(2): 228–229. https://doi.org/10.28996/2618-9801-2025-2-228-229. EDN: ABCXTZ

11. Gatseva A., Sin Y.Y., Brezzo G., Van Agtmael T. Basement membrane collagens and disease mechanisms. Essays Biochem. 2019 Sep; 63(3): 297–312. https://doi.org/10.1042/EBC20180071. PMID: 31387942

12. Lee J.M., Nozu K., Choi D.E., et al. Features of autosomal recessive Alport syndrome: A systematic review. J Clin Med. 2019 Feb; 8(2): 178. https://doi.org/10.3390/jcm8020178. PMID: 30717457

13. Zhang Y., Böckhaus J., Wang F., et al. Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome. Pediatr Nephrol. 2021 Sep; 36(9): 2719–2730. https://doi.org/10.1007/s00467-021-05040-9. Epub 2021 Mar 27. PMID: 33772369

14. Shulman C., Liang E., Kamura M., et al. Type IV collagen variants in CKD: Performance of computational predictions for identifying pathogenic variants. Kidney Med. 2021 Feb; 3(2): 257–266. https://doi.org/10.1016/j.xkme.2020.12.007. PMID: 33851121

15. Savige J., Lipska-Zietkiewicz B.S., Watson E., et al. Guidelines for genetic testing and management of Alport syndrome. Clin J Am Soc Nephrol. 2022 Jan; 17(1): 143–154. https://doi.org/10.2215/CJN.04230321. Epub 2021 Dec 20. Erratum in: Clin J Am Soc Nephrol. 2023 Apr 1; 18(4): 510. https://doi.org/10.2215/CJN.0000000000000095. PMID: 34930753

16. Groopman E.E., Marasa M., Cameron-Christie S., et al. Diagnostic utility of exome sequencing for kidney disease. N Engl J Med. 2019 Jan; 380(2): 142–151. https://doi.org/10.1056/NEJMoa1806891. Epub 2018 Dec 26. PMID: 30586318

17. Thanachatchairattana P., Losty P. Paediatric diffuse oesophageal leiomyomatosis with Alport syndrome. BMJ Case Rep. 2024 Aug; 17(8): e260442. https://doi.org/10.1136/bcr-2024-260442. PMID: 39179268

18. Flinter F.A., Cameron J.S., Chantler C., et al. Genetics of classic Alport’s syndrome. Lancet. 1988 Oct; 2(8618): 1005–1007. https://doi.org/10.1016/s0140-6736(88)90753-2. PMID: 2902439

19. Chen F., Ahimaz P., Nguyen Q.M., et al. Phenotype driven molecular genetic test recommendation for diagnosing pediatric rare disorders. NPJ Digit Med. 2024 Nov; 7(1): 333. https://doi.org/10.1038/s41746-024-01331-1. PMID: 39572625

20. Аксенова М.Е. Синдром Альпорта: современные представления. Нефрология. 2021; 25(3): 75–83. https://doi.org/10.36485/1561-6274-2021-25-3-75-83. EDN: LYSGFH

21. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024 Apr; 105(4S): S117–S314. https://doi.org/10.1016/j.kint.2023.10.018. PMID: 38490803

22. Gibson J.T., de Gooyer M., Huang M., Savige J. A systematic review of pathogenic COL4A5 variants and proteinuria in women and girls with X-linked Alport syndrome. Kidney Int Rep. 2022 Aug; 7(11): 2454–2461. https://doi.org/10.1016/j.ekir.2022.08.021. PMID: 36531881

23. Kim J.H., Lim S.H., Song J.Y., et al. Genotype-phenotype correlation of X-linked Alport syndrome observed in both genders: a multicenter study in South Korea. Sci Rep. 2023 Apr; 13(1): 6827. https://doi.org/10.1038/s41598-023-34053-7. PMID: 37100867

24. Matthaiou A., Poulli T., Deltas C. Prevalence of clinical, pathological and molecular features of glomerular basement membrane nephropathy caused by COL4A3 or COL4A4 mutations: a systematic review. Clin Kidney J. 2020 Feb; 13(6): 1025–1036. https://doi.org/10.1093/ckj/sfz176. PMID: 33391746


补充文件

评论

浏览: 200


ISSN 2218-7332 (Print)
ISSN 2658-3348 (Online)